Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLC
Sun Min Lim1, Chang Gon Kim1, Jii Bum Lee1,2
1Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
Abstract:
HER3 is ubiquitously expressed in EGFR-mutant non-small cell lung cancer (NSCLC) irrespective of resistant mechanisms to EGFR tyrosine kinase inhibitors, thus garnering attention as a valuable therapeutic target. In this issue of Cancer Discovery, Jänne and colleagues highlight early clinical data supporting patritumab deruxtecan as a potentially appreciable agent for previously treated EGFR-mutant NSCLC.See related article by Jänne et al., p. 74.
Insights
HER3 is a target in EGFR-mutant non-small cell lung cancer (NSCLC). Early data show patritumab deruxtecan may benefit previously treated NSCLC patients with this mutation.
Area of Science:
- Oncology
- Molecular Biology
- Clinical Trials
Background:
- HER3 is widely expressed in EGFR-mutant non-small cell lung cancer (NSCLC).
- HER3 expression persists despite resistance to EGFR tyrosine kinase inhibitors.
- This makes HER3 a significant therapeutic target in NSCLC.
Purpose of the Study:
- To evaluate patritumab deruxtecan as a treatment for previously treated EGFR-mutant NSCLC.
- To highlight early clinical data for this novel therapeutic approach.
Main Methods:
- Review of early clinical data for patritumab deruxtecan.
- Analysis of HER3 expression in EGFR-mutant NSCLC.
Main Results:
- Patritumab deruxtecan shows potential as an effective agent.
- The drug is being considered for patients with previously treated EGFR-mutant NSCLC.
Conclusions:
- Patritumab deruxtecan represents a promising therapeutic option.
- Further clinical investigation is warranted for this targeted therapy in NSCLC.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
